Suma Krishnan, President, R&D at Krystal Biotech, Inc. (KRYS), sold 99,800 shares at $215.49 ($20.9M) on 2025-12-04, disclosed to the SEC on 2025-12-05.
Scheduled sale ($20.9M) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $214.25 | 700 | $150K | 0.7% |
| 2 | $214.28 | 956 | $205K | 1.0% |
| 3 | $214.28 | 956 | $205K | 1.0% |
| 4 | $215.48 | 344 | $74K | 0.4% |
| 5 | $215.48 | 344 | $74K | 0.4% |
| 6 | $215.49 | 600 |
| $129K |
| 0.6% |
| 7 | $216.97 | 1,400 | $304K | 1.5% |
| 8 | $217.04 | 1,600 | $347K | 1.7% |
| 9 | $218.72 | 2,577 | $564K | 2.7% |
| 10 | $218.72 | 2,577 | $564K | 2.7% |
| 11 | $218.83 | 3,593 | $786K | 3.8% |
| 12 | $218.83 | 3,593 | $786K | 3.8% |
| 13 | $219.53 | 5,693 | $1.2M | 6.0% |
| 14 | $219.53 | 5,693 | $1.2M | 6.0% |
| 15 | $219.68 | 5,419 | $1.2M | 5.7% |
| 16 | $219.68 | 5,419 | $1.2M | 5.7% |
| 17 | $220.34 | 2,625 | $578K | 2.8% |
| 18 | $220.34 | 2,625 | $578K | 2.8% |
| 19 | $220.52 | 2,627 | $579K | 2.8% |
| 20 | $220.52 | 2,627 | $579K | 2.8% |
| 21 | $221.78 | 10,505 | $2.3M | 11.2% |
| 22 | $221.78 | 10,505 | $2.3M | 11.2% |
| 23 | $221.82 | 10,461 | $2.3M | 11.1% |
| 24 | $221.82 | 10,461 | $2.3M | 11.1% |
| 25 | $222.20 | 700 | $156K | 0.7% |
| 26 | $222.38 | 200 | $44K | 0.2% |
| 27 | $0.00 | 5,000 | $0 | 0.0% |
| Total | $209.26 avg | 99,800 | $20.9M | 100% |
| Filing → |
| KRYS | SELL | 2026-03-06 | $13.2M | — | Filing → |
| KRYS | SELL | 2025-07-16 | $10.1M | — | Filing → |
| KRYS | SELL | 2025-07-11 | $4.0M | — | Filing → |